Replies to post #48117 on Amarantus Bioscience Holdings Inc (AMBS)

[StockDog OTC]

AMBS - As MANF continues forward in its development, the Company expects to build the most accretive value in the near-term from its diagnostic assets. As previously discussed, the Company is now in an excellent negotiating position with potential partners and investors interested in advancing our diagnostic candidates forward on favorable terms so we can devote the majority of our internal resources to our MANF programs in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and the evaluation of certain orphan indications. We will update the marketplace regarding our diagnostic assets and plans for their continued development in the near future.

In closing, the future has never looked brighter for Amarantus. We have unambiguous data supporting MANF’s further development in our lead Parkinson’s disease indication, we now have rights to seven diagnostic blood tests in significant markets, and our MANF asset continues to make progress in secondary indications. We are looking forward to an exciting 2013 for the Company and its shareholders.

I thank you for taking the time to read this letter and looking forward to communicating with you in the future.

Sincerely,
Gerald E. Commissiong
President & Chief Executive Officer


CEO BLOG (1/14/2013) Onwards and Upwards: Building Value From a Solid Foundation

SOURCE: http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html




Website - http://www.amarantus.com

[Rotten Johnny]

exactly look well past the fundamentals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83647979